dc.contributor.author | Drapkin, R. | |
dc.contributor.author | Dreaden, Erik | |
dc.contributor.author | Kong, Yi Wen | |
dc.contributor.author | Morton, Stephen Winford | |
dc.contributor.author | Correa Echavarria, Santiago | |
dc.contributor.author | Choi, Ki Young | |
dc.contributor.author | Shopsowitz, Kevin | |
dc.contributor.author | Renggli-Frey, Kasper | |
dc.contributor.author | Yaffe, Michael B | |
dc.contributor.author | Hammond, Paula T | |
dc.date.accessioned | 2016-12-19T16:11:11Z | |
dc.date.available | 2016-12-19T16:11:11Z | |
dc.date.issued | 2015-06 | |
dc.date.submitted | 2015-04 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.issn | 1557-3265 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/105871 | |
dc.description.abstract | Purpose: Cross-talk and feedback between the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell signaling pathways is critical for tumor initiation, maintenance, and adaptive resistance to targeted therapy in a variety of solid tumors. Combined blockade of these pathways—horizontal blockade—is a promising therapeutic strategy; however, compounded dose-limiting toxicity of free small molecule inhibitor combinations is a significant barrier to its clinical application.
Experimental Design: AZD6244 (selumetinib), an allosteric inhibitor of Mek1/2, and PX-866, a covalent inhibitor of PI3K, were co-encapsulated in a tumor-targeting nanoscale drug formulation—layer-by-layer (LbL) nanoparticles. Structure, size, and surface charge of the nanoscale formulations were characterized, in addition to in vitro cell entry, synergistic cell killing, and combined signal blockade. In vivo tumor targeting and therapy was investigated in breast tumor xenograft-bearing NCR nude mice by live animal fluorescence/bioluminescence imaging, Western blotting, serum cytokine analysis, and immunohistochemistry.
Results: Combined MAPK and PI3K axis blockade from the nanoscale formulations (160 ± 20 nm, −40 ± 1 mV) was synergistically toxic toward triple-negative breast (MDA-MB-231) and RAS-mutant lung tumor cells (KP7B) in vitro, effects that were further enhanced upon encapsulation. In vivo, systemically administered LbL nanoparticles preferentially targeted
subcutaneous MDA-MB-231 tumor xenografts, simultaneously blocked tumor-specific phosphorylation of the terminal kinases Erk and Akt, and elicited significant disease stabilization in the absence of dose-limiting hepatotoxic effects observed from the free drug combination. Mice
receiving untargeted, but dual drug-loaded nanoparticles exhibited progressive disease.
Conclusions: Tumor-targeting nanoscale drug formulations could provide a more safe and effective means to synergistically block MAPK and PI3K in the clinic. | en_US |
dc.description.sponsorship | United States. Department of Defense (OCRP Teal Innovator Award) | en_US |
dc.description.sponsorship | National Institutes of Health (U.S.) (Grant NIBIB 1F32EB017614-02) | en_US |
dc.description.sponsorship | Misrock Foundation | en_US |
dc.description.sponsorship | National Science Foundation (U.S.) | en_US |
dc.description.sponsorship | Swiss National Science Foundation | en_US |
dc.description.sponsorship | David H. Koch Institute for Integrative Cancer Research at MIT (Support Grant P30-CA14051) | en_US |
dc.description.sponsorship | National Cancer Institute (U.S.) | en_US |
dc.description.sponsorship | National Science Foundation (U.S.) (Massachusetts Institute of Technology. Materials Research Science and Engineering Center. Shared Experimental Facilities Grant DMR-0819762) | en_US |
dc.description.sponsorship | Breast Cancer Alliance (Exceptional Project Grant) | en_US |
dc.language.iso | en_US | |
dc.publisher | American Association for Cancer Research | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1158/1078-0432.ccr-15-0013 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
dc.source | PMC | en_US |
dc.title | Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Dreaden, E. C. et al. “Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.” Clinical Cancer Research 21.19 (2015): 4410–4419. | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biological Engineering | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
dc.contributor.mitauthor | Dreaden, Erik | |
dc.contributor.mitauthor | Kong, Yi Wen | |
dc.contributor.mitauthor | Morton, Stephen Winford | |
dc.contributor.mitauthor | Correa Echavarria, Santiago | |
dc.contributor.mitauthor | Choi, Ki Young | |
dc.contributor.mitauthor | Shopsowitz, Kevin | |
dc.contributor.mitauthor | Renggli-Frey, Kasper | |
dc.contributor.mitauthor | Yaffe, Michael B | |
dc.contributor.mitauthor | Hammond, Paula T | |
dc.relation.journal | Clinical Cancer Research | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Dreaden, E. C.; Kong, Y. W.; Morton, S. W.; Correa, S.; Choi, K. Y.; Shopsowitz, K. E.; Renggli, K.; Drapkin, R.; Yaffe, M. B.; Hammond, P. T. | en_US |
dspace.embargo.terms | N | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-4954-8443 | |
dc.identifier.orcid | https://orcid.org/0000-0002-4223-971X | |
dc.identifier.orcid | https://orcid.org/0000-0001-8230-4945 | |
dc.identifier.orcid | https://orcid.org/0000-0002-8848-7559 | |
dc.identifier.orcid | https://orcid.org/0000-0003-3988-0837 | |
dc.identifier.orcid | https://orcid.org/0000-0001-6865-4084 | |
dc.identifier.orcid | https://orcid.org/0000-0002-9547-3251 | |
mit.license | OPEN_ACCESS_POLICY | en_US |